The MeCRU Clinical Research Unit (MeCRU) has played a pivotal role in advancing clinical research in South Africa since its establishment in 2005. Situated at Sefako Makgatho Health Sciences University (SMU), MeCRU has dedicated itself to tackling pressing public health challenges, particularly those related to HIV/AIDS, tuberculosis (TB), and other communicable diseases.
Under the leadership of Professor Maphoshane Nchabeleng (site principal investigator), Dr Matsontso Mathebula (site sub-investigator), and Nontando Moeketsi (site project manager), MeCRU continues to make significant contributions to clinical research while fostering community engagement and ethical research practices.
MeCRU was founded in October 2005 to address South Africa’s critical health concerns, particularly the HIV/AIDS epidemic. “The goal was to create a clinical research centre that not only advances scientific knowledge but also translates research discoveries into practical health interventions,” says Nchabeleng. The unit was also designed to enhance local research capacity and contribute to global efforts to combat infectious diseases.
Support from the South African AIDS Vaccine Initiative (SAAVI) and the Medical Research Council (MRC) was instrumental in establishing MeCRU. SAAVI’s commitment to developing an HIV vaccine helped position the unit as a key player in clinical research, while the MRC provided expertise in research methodology and ethics, ensuring that MeCRU adhered to international standards.
A defining moment for MeCRU came in 2010 when the unit was officially launched by then Minister of Health, Dr Aaron Motsoaledi. “This event underscored government support for clinical trials and vaccine research, reinforcing the need for local solutions to local health challenges,” notes Moeketsi.
Over the years, MeCRU has conducted several transformative studies. Among its most impactful research projects is the ensemble study, which evaluated the efficacy of the Johnson & Johnson COVID-19 vaccine. The unit has also contributed to TB vaccine development, particularly in finding alternatives to the BCG vaccine. “Our research on biomarkers for drug-resistant TB has the potential to change how we predict and prevent TB relapses,” explains Mathebula.
One of MeCRU’s defining strengths is its commitment to ethical research and community engagement. The Community Advisory Group (CAG) plays a crucial role in bridging the gap between researchers and the public. “CAG ensures that research methods align with community values and concerns, fostering trust and collaboration,” says Nchabeleng. This engagement is crucial in addressing scepticism and promoting participation in clinical trials.
MeCRU also prioritises participant safety through strict ethical guidelines, informed consent procedures, and ongoing monitoring of study outcomes. Independent ethics committees and external monitors further ensure that all trials meet the highest standards of integrity.
MeCRU houses an accredited Contract Research Laboratory (MLS), which provides essential laboratory support for clinical trials. “The laboratory plays a vital role in molecular biology, serology, and bacteriology research, helping advance diagnostic methods and treatment strategies,” says Mathebula. The facility adheres to international accreditation standards, ensuring the reliability of research findings.
Looking ahead, MeCRU aims to solidify its position as a leading clinical research site. “We hope to expand our research capabilities and secure sustainable funding through international collaborations and pharmaceutical partnerships,” explains Moeketsi. Upcoming projects include studies on Group B Streptococcus vaccines, tuberculosis vaccine trials, and further research into HIV prevention.
MeCRU also seeks to involve more SMU researchers in clinical trials. “There is a wealth of expertise at SMU, and we encourage faculty members to take on principal investigator roles. We provide the necessary regulatory and community support to facilitate high-quality research,” says Nchabeleng.
MeCRU’s motto, ‘Empowering the Community Towards Healthcare Solutions,’ reflects its commitment to improving public health. Through outreach programmes, health education initiatives, and vaccination campaigns, the unit actively contributes to community well-being. “We are not just conducting research; we are making a tangible difference in people’s lives,” says Mathebula.
As MeCRU continues to grow, its contributions to clinical research and community health will remain invaluable. With its dedication to scientific excellence and ethical research, the unit is well-positioned to lead groundbreaking studies that will shape the future of healthcare in South Africa and beyond.
By Tumelo Moila
